135 related articles for article (PubMed ID: 18312904)
1. Neutral endopeptidase inhibitors and endothelin antagonists.
Iyengar S; Abraham WT
Cardiol Clin; 2008 Feb; 26(1):41-8, vi. PubMed ID: 18312904
[TBL] [Abstract][Full Text] [Related]
2. Traditional and novel approaches to management of heart failure: successes and failures.
Anand IS; Florea VG
Cardiol Clin; 2008 Feb; 26(1):59-72, vi. PubMed ID: 18312906
[TBL] [Abstract][Full Text] [Related]
3. Neutral endopeptidase inhibitors and endothelin antagonists: why did the clinical trials not demonstrate beneficial effects?
Iyengar S; Abraham WT
Heart Fail Clin; 2005 Apr; 1(1):95-102. PubMed ID: 17386837
[No Abstract] [Full Text] [Related]
4. Neurohormonal inhibition in heart failure: insights from recent clinical trials.
Gheorghiade M; De Luca L; Bonow RO
Am J Cardiol; 2005 Dec; 96(12A):3L-9L. PubMed ID: 16399087
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy.
Dobrek Ł; Thor P
Acta Pol Pharm; 2011; 68(3):307-16. PubMed ID: 21648184
[TBL] [Abstract][Full Text] [Related]
6. [Refractory heart failure. Antagonism of tumor necrosis factor alpha and endothelin in humans: 2 promises still to be honored].
Valgimigli M; Ferrari R; Masson S; Latini R
Ital Heart J Suppl; 2002 Aug; 3(8):793-803. PubMed ID: 12407834
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials of endothelin antagonists in heart failure: a question of dose?
Kelland NF; Webb DJ
Exp Biol Med (Maywood); 2006 Jun; 231(6):696-9. PubMed ID: 16740982
[TBL] [Abstract][Full Text] [Related]
8. Role of endothelins in congestive heart failure.
Moe GW; Rouleau JL; Nguyen QT; Cernacek P; Stewart DJ
Can J Physiol Pharmacol; 2003 Jun; 81(6):588-97. PubMed ID: 12839270
[TBL] [Abstract][Full Text] [Related]
9. Endothelin-converting enzyme inhibitors: their application in cardiovascular diseases.
Cerdeira AS; Brás-Silva C; Leite-Moreira AF
Rev Port Cardiol; 2008 Mar; 27(3):385-408. PubMed ID: 18551924
[TBL] [Abstract][Full Text] [Related]
10. [Endothelin system and heart failure: a potential therapeutic target].
Vaz-da-Silva M; Abreu-Lima C
Rev Port Cardiol; 2004 May; 23 Suppl 2():II81-93. PubMed ID: 15222252
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic.
Mariotti R; Borelli G; Coceani M; Zingaro S; Barison A; Morelli I; Rondinini L
J Clin Pharm Ther; 2008 Aug; 33(4):349-56. PubMed ID: 18613852
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
Olimpieri F; Tambaro S; Fustero S; Lazzari P; Sanchez-Roselló M; Pani L; Volonterio A; Zanda M
Bioorg Med Chem Lett; 2009 Aug; 19(16):4715-9. PubMed ID: 19596577
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin receptor--neprilysin inhibiton (ARNI)--a novel therapeutic concept for management of hypertension and heart failure.
Kjeldsen SE; Hedner T; Narkiewicz K; Oparil S
Blood Press; 2012 Dec; 21(6):329-30. PubMed ID: 23210746
[No Abstract] [Full Text] [Related]
14. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators.
Cleland JG; Swedberg K
Lancet; 1998 May; 351(9116):1657-8. PubMed ID: 9620738
[No Abstract] [Full Text] [Related]
15. Potential novel pharmacological therapies for myocardial remodelling.
Landmesser U; Wollert KC; Drexler H
Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
[TBL] [Abstract][Full Text] [Related]
16. Phosphonamide inhibitors of neutral endopeptidase (EC 3.4.24.11).
Norcini G; Morazzoni G; Pocchiari F; Santangelo F; Semeraro C
J Enzyme Inhib; 1997 Apr; 12(1):71-7. PubMed ID: 9204384
[No Abstract] [Full Text] [Related]
17. Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis.
Wang BH; von Lueder TG; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
Int J Cardiol; 2015; 186():104-5. PubMed ID: 25828104
[No Abstract] [Full Text] [Related]
18. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
Makkar KM; Sanoski CA; Spinler SA
Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
[TBL] [Abstract][Full Text] [Related]
19. Advances in the treatment of heart failure with a preserved ejection fraction.
Das A; Abraham S; Deswal A
Curr Opin Cardiol; 2008 May; 23(3):233-40. PubMed ID: 18382212
[TBL] [Abstract][Full Text] [Related]
20. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
